BRAF and Langerhans cell histiocytosis: Finally, recent data points to a high prevalence of BRAF V600E mutations among ECD and LCH patients [18,89] advocating the possible usage of BRAF inhibitors such as vemurafenib in the targeted treatment of ECD.